An anti-malarial compound first synthesised at IRL, BCX4945, has successfully passed the first stage of a pre-clinical efficacy study, raising the hope of a new weapon in the war against the deadly disease.
Kerry Paul is the CEO of Manuka Health New Zealand. With a strong focus on adding value to New Zealand natural health products, Manuka Health has been working with IRL on the technology transfer of a new innovation, CycloPower™. We asked Kerry to tell us more.
The international profile of New Zealand’s emerging high temperature superconductivity (HTS[?]) industry gained a boost recently when IRL and some of its commercialisation partners showcased HTS capabilities at several high-profile events in Europe.